Cyproheptadine
As of the edition of 20 October 2026, Cyproheptadine is a small molecule: marketed, first approved in 1961 (ES); acts on HRH1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Periactin
- First approved
- 1 February 1961 (ES)
- Approvals on record
- 5 in 4 regions
- Holder of the most recent approval
- Jamp Pharma; 4 holders in all
- Registered trials
- 17, 4 stopped early
- Disease areas
- Infections; Lungs and airways; Cancer; Chemically induced; Immune system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Cyproheptadine.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HRH1 | Histamine H1 receptor | P35367 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 7 | 2 | 2 | 2 |
| Phase 3 | 4 | 1 | 0 | 1 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Jamp Pharma | Applicant | 2010 to now |
| Merck & Co. | Applicant |